Article
Reducing the global burden of HTLV-1 infection: An agenda for research and action
Registro en:
WILLEMS, Luc et al. Reducing the global burden of HTLV-1 infection: An agenda for research and action. Antiviral Research, v. 137, p. 41-48, 2017
0166-3542
10.1016/j.antiviral.2016.10.015
Autor
Willems, Luc
Hasegawa, Hideki
Accolla, Roberto
Bangham, Charles
Bazarbachi, Ali
Bertazzoni, Umberto
Proietti, Anna Barbara de Freitas Carneiro
Cheng, Hua
Bianchi, Luigi Chieco
Ciminale, Vincenzo
Reis, Jordana Grazziela Alves Coelho dos
Esparza, Jose
Gallo, Robert C.
Gessain, Antoine
Gotuzzo, Eduardo
Hall, William
Harford, Joseph
Hermine, Olivier
Jacobson, Steven
Macchi, Beatrice
Macpherson, Calum
Mahieux, Renaud
Matsuoka, Masao
Murphy, Edward
Peloponese, Jean-Marie
Simon, Viviana
Tagaya, Yutaka
Taylor, Graham P
Watanabe, Toshiki
Yamano, Yoshihisa
Resumen
Even though an estimated 10e20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort hás been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. 2023-01-01